MFDS Approves Treatment for Paroxysmal Nocturnal Hemoglobinuria
Broader Treatment Options for Pediatric Patients with Imported Orphan Drug "PiaSky Injection"
The Ministry of Food and Drug Safety announced on December 24 that it has approved the imported orphan drug "PiaSky Injection" (active ingredient: crovalimab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults weighing 40 kg or more and pediatric patients aged 12 years and older.
Paroxysmal nocturnal hemoglobinuria is an acquired hematopoietic stem cell disorder characterized by hemolysis, a phenomenon in which hemoglobin escapes from red blood cells, resulting in dark-colored urine at night.
PiaSky Injection suppresses complement-mediated intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. The complement system is a group of proteins that attack bacteria and viruses and assist immune responses.
This drug has been approved for use in pediatric patients for the first time.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Ministry of Food and Drug Safety expressed its expectation that this approval will expand the range of treatment options for both adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.